Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 29, 2019 06:55 ET | Source: Interpace Diagnostics Group, Inc.

Interpace Announces Contract with Blue Shield of California for ThyGeNEXT® & ThyraMIR®

Four Million Members Gain in-Network Access PARSIPPANY, NJ, July 29, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it has entered in to a contract...
July 22, 2019 06:55 ET | Source: Interpace Diagnostics Group, Inc.

Interpace Announces New Agreement with SelectHealth

Expected to Benefit More than 850,000 Members PARSIPPANY, NJ, July 22, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it has reached an agreement...
July 18, 2019 06:55 ET | Source: Interpace Diagnostics Group, Inc.

Interpace Diagnostics Enters Agreement with Predictive Oncology to Enhance Diagnosis of Thyroid Cancer Via AI-Driven Analysis

PARSIPPANY, NJ, July 18, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace” or the “Company), announced today that it has executed an agreement with the Helomics...
July 15, 2019 16:10 ET | Source: Interpace Diagnostics Group, Inc.

Interpace Diagnostics Acquires Cancer Genetics’ Biopharma Services Business Supported by Investment from Ampersand Capital Partners

Conference Call to be Held Tomorrow, Tuesday July 16, 2019 @ 8:30 am ET PARSIPPANY NJ, July 15, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace” or the...
June 20, 2019 06:55 ET | Source: Interpace Diagnostics Group, Inc.

Interpace Diagnostics Announces Coverage of Molecular Thyroid Testing by Independence Blue Cross

PARSIPPANY NJ, June 20, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that its ThyGeNEXT™ and ThyraMIR® tests for thyroid cancer are now covered by...
June 13, 2019 06:55 ET | Source: Interpace Diagnostics Group, Inc.

Interpace Diagnostics Announces Presentation at the World Congress on Thyroid Cancer

Rome, ITALY, June 13, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG), a fully integrated bioinformatics and commercial molecular diagnostic company, today announced that...
May 13, 2019 16:05 ET | Source: Interpace Diagnostics Group, Inc.

Interpace Diagnostics Reports First Quarter 2019 Financial Results and Provides Business Update

Quarterly Revenue Grew to $6.0 Million, a 25% Increase Year-over-Year Annual 2019 Revenue Guidance of $27 to $28 Million, a 25% Increase Conference Call and Webcast Monday May 13, 2019 at 4:30...
May 09, 2019 06:55 ET | Source: Interpace Diagnostics Group, Inc.

Interpace Diagnostics BarreGEN® Data to be Presented at Digestive Disease Week

Company to Host Fellowship and Key Opinion Leader Programs PARSIPPANY, NJ, May 09, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that data from an...
May 06, 2019 06:55 ET | Source: Interpace Diagnostics Group, Inc.

Interpace Diagnostics to Host Conference Call and Webcast to Discuss First Quarter 2019 Financial Results on Monday, May 13, 2019

PARSIPPANY, NJ, May 06, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc., (IDXG:NASDAQ) announced today that it will report its first quarter 2019 financial results after the close of...
May 01, 2019 06:55 ET | Source: Interpace Diagnostics Group, Inc.

Interpace Diagnostics Announces Publication of Important New Data on Thyroid Test Performance

Data from Registry Study Confirms the Value of ThyGenX® and ThyraMIR® in a Clinical Setting PARSIPPANY, NJ, May 01, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc....